ReviewFrontiers in nutrition2026
Targeting cellular senescence through nutritional senotherapeutics in brain aging and neurodegenerative diseases.
Review in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- AgeViva Modulates Inflammatory Responses, Autophagy, and Mitochondrial Homeostasis in BV-2 Cells andMetabolites · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cellular senescence has emerged as a key contributor to brain aging and neurodegenerative diseases, which are increasing in prevalence as life expectancy rises. Senescent cells accumulate in multiple brain cell populations and secrete the senescence-associated secretory phenotype (SASP), promoting chronic neuroinflammation, mitochondrial dysfunction, blood-brain barrier disruption, and progressive neuronal damage. This review examines the role of cellular senescence in brain aging and neurodegenerative diseases and discusses senotherapeutic strategies aimed at either eliminating senescent cells (senolytics) or modulating the SASP (senomorphics). Particular emphasis is placed on nutritional senotherapeutics, naturally occurring bioactive compounds derived from dietary sources that target molecular pathways involved in cellular senescence. Senomorphic compounds such as sulforaphane, curcumin, and resveratrol primarily attenuate oxidative stress and inflammatory signaling, whereas senolytic agents including quercetin and fisetin selectively promote the elimination of senescent cells by disrupting pro-survival pathways. Current evidence from experimental models and emerging clinical studies suggests that nutritional senotherapeutics represent promising complementary strategies for modulating cellular senescence and promoting brain health. However, their clinical translation remains constrained by limited human evidence, low bioavailability, and unresolved challenges related to optimal dosing and blood-brain barrier penetration, highlighting the need for well-designed clinical trials before their therapeutic potential can be fully established.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.